多重系统缩的一个子组,生命能力迅速下降
So Okubo1, Kenta Orimo1, Takashi Matsukawa1
1Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Journal of the neurological sciences
|January 10, 2025
概括
多重系统缩 (MSA) 和渐进性上核性麻 (PSP) 的肺功能随着疾病持续时间的下降而下降. MSA表现出更大的变异性,MSA-P患者在疾病的早期经常出现快速的生命能力下降.
科学领域:
- 神经学 神经学
- 肺部病理学 肺部病理学
- 医学研究 医学研究
背景情况:
- 像MSA和PSP这样的神经退行性疾病往往会导致食障碍,需要胃口修复.
- 肺功能测试 (PFT) 对这些患者的手术前评估至关重要.
- 有限的数据存在于MSA和PSP的肺功能变化.
研究的目的:
- 调查多发性系统缩 (MSA) 和渐进性上核性麻 (PSP) 患者的肺功能测试 (PFT) 模式.
- 分析MSA和PSP中肺功能下降和疾病持续时间之间的相关性.
- 为了确定MSA和PSP之间的肺功能进展的差异.
主要方法:
- 对MSA和PSP患者的PFT记录进行了回顾性分析.
- 纳入标准:2012年1月至2023年10月期间入院的患者.
- 分析的数据包括生命能力百分比 (%VC) 和疾病持续时间.
主要成果:
- 在MSA (r=-0.34) 和PSP (r=-0.19) 两种情况下,在%VC和疾病持续时间之间发现了弱负相关性.
- 与PSP相比,肺功能下降显示MSA的变化更大.
- 7名MSA患者 (6名MSA-P,1名MSA-C) 在5年内经历了快速的%VC下降 (<65%).
结论:
- 肺功能,特别是%VC,在MSA和PSP中随着时间的推移而下降.
- 在VC%的下降中,MSA表现出比PSP更显著的变化.
- 快速%VC下降在MSA-P的早期更为常见.
相关概念视频
Acute Respiratory Failure-III
154
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
154
Acute Respiratory Failure-IV
125
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
125
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Acute Respiratory Failure-II
171
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
171
Acute Respiratory Failure-I
163
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
163
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K


